Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) reported results from an Phase Ib/II study sponsored by MD Anderson during the European Hematology Association meeting in June 2016, detailing the effect of a combination of Qinprezo and Dacogen for the frontline treatment of patients with acute myeloid leukemia (AML) and those with myelodysplastic syndrome (MDS) unfit for intensive therapy. The 63-person open-label trial demonstrated a median overall survival of 16.1 months at the 70mg/m2 Qinprezo dose, over twice that of either of the drugs alone.
Lower Qinprezo dose outperformed higher dose
The trial protocol was amended following a high rate of mucositis from 90mg/m2 Qinprezo (on days one and four of a five-day cycle) to 70mg/m2, both in combination with 20mg/m2 Dacogen (daily). The patients on the lower Qinprezo dose showed a substantially improved overall survival at 16.1 months compared to 5.5 months and reduced early death (at eight weeks) to 5% from 27%.
To read the entire report Please click on the pdf File Below